- 2 active bonds tracked from this issuer.
- 2 of 2 tracked bonds with a stated security status are secured. (based on 2 bonds with a disclosed security status)
Hydra Active Pharma Sciences Private Limited, a corporate issuer, is tracked on RetailBonds.in. Maturities on outstanding bonds fall between 2030 - 2030.
Data sourced from NSDL, BSE, NSE, and registered credit rating agencies. Verify against the issuer's offer document before transacting.
Thanks — your suggestion has been submitted for review.
Maturity Profile
Active bonds maturing, by year. Bar height relative to the tallest year (2 bonds).
Security Type / Instrument Mix
- NCD 2 bonds · 100% · ₹198 Cr tracked
Funding Evolution
Based on 2 of 2 active bonds with a known issue date and issue size.
- Unrated 2 bonds · 100%
Recent Rating Actions
No rating action history available.
| ISIN | Bond Name | Coupon | Rating | Maturity | YTM | Last Trade | |
|---|---|---|---|---|---|---|---|
| INE08OI07021 | SECURED UNRATED UNLISTED REDEEMABLE NON CONVERTIBLE DEBENTURE SERIES B DATE OF MATURITY 20/05/2030 | — | — | 2030-05-20 | 14.00% | 2026-08-04 | |
| INE08OI07013 | SECURED UNRATED UNLISTED REDEEMABLE NON CONVERTIBLE DEBENTURE SERIES A DATE OF MATURITY 21/05/2030 | — | — | 2030-05-21 | — | — |
YTM and Last Trade depend on secondary-market volume — shown only for bonds with a recorded BSE/NSE trade.
Last 30 days, across all outstanding bonds from this issuer.
No regulatory filings captured yet for this issuer.
| Dataset | Count | Freshness |
|---|---|---|
| Credit Ratings (current) | 0 | — |
| Rating Actions History | 0 | — |
| Secondary-Market Trades | 7 | 2026-08-04 |
| Reg52(4) Payment Disclosures | 0 | — |
Methodology version 1.0. See full methodology for sources and limitations.
Related Issuers
All issuers →Disclaimer: This page aggregates publicly available data about Hydra Active Pharma Sciences Private Limited for informational purposes only. Ratings shown are the opinion of the issuing rating agency and are not buy/sell recommendations. RetailBonds.in does not issue its own ratings or investment advice. Verify all data against the issuer’s offer document before transacting.